News Release

Brain molecule makes neurons less selective, deepening understanding of human cognition

Findings from Johns Hopkins Medicine may help scientists better understand causes of autism, schizophrenia and epilepsy

Peer-Reviewed Publication

Johns Hopkins Medicine

Excitatory neurons from the brains of mice

image: 

Excitatory neurons from the brains of mice are depicted in green, and PV inhibitory neurons are pictured in magenta. Cells are depicted in the deep hippocampus, which helps navigate space, toward the left side of the image. Toward the right side, cells are depicted in the visual cortex.

view more 

Credit: David Cheon and Ingie Hong

**EMBARGOED FOR RELEASE UNTIL WEDNESDAY, OCT. 2, AT 11 A.M. ET**

Neuroscientists from Johns Hopkins Medicine say they have determined how a brain cell surface molecule shapes the way certain neurons behave.

The research, published October 2 in Nature, reveals how a molecule, the calcium permeable (CP)-AMPA receptor, suppresses a specific neuron’s ability to pay attention to specific external cues, such as your friend’s earrings, according to the study in genetically-engineered mice. Understanding why some neurons are less “selective” about their response to certain cues may also help researchers study schizophrenia, epilepsy and autism — conditions marked by the faulty processing of external cues and misfirings of neurons in the mammalian brain.

“We've discovered that the calcium permeable subtype of AMPA receptors has an added role of suppressing the selectivity of a given neuron,” says Ingie Hong, Ph.D., first author and an instructor in neuroscience at the Johns Hopkins University Medicine. “Until now, the role of these specific receptors in the wider mammalian brain as it functions in everyday life has been a mystery.”

Along with Hong, the research was led by Richard Huganir, Ph.D., Bloomberg Distinguished Professor of Neuroscience and Psychological and Brain Sciences and director of the Solomon H. Snyder Department of Neuroscience at the Johns Hopkins University School of Medicine, who has been studying AMPA receptors for more than 40 years.

AMPA receptors are critical to the fast transfer of information and memory formation in the brain, such as hearing and remembering a person’s name. The subtype of AMPA receptors in this study, CP-AMPA receptors, act as a “gate” that lowers the selectivity of parvalbumin (PV) neurons, which are inhibitory and thereby cast unselective inhibition to nearby neurons, the researchers say.

“Selective neurons will respond to something really specific, for example, your grandfather’s mustache, whereas less selective neurons will respond to different faces or people as well,” Hong says. “We’ve been looking for the mechanisms and molecules that control this specificity, or selectivity, and how it goes awry in conditions such as autism and epilepsy, where excitatory neurons can become overstimulated.”   

The researchers also found that mutations of GluA2, a protein subunit within the CP-AMPA receptor, are associated with intellectual disabilities.

“Human mutations in the GluA2 subunit of the AMPA receptors, which regulates the calcium permeability of the receptor, can lead to intellectual disability and autism,” says senior author Huganir. “This suggests tight control of AMPA receptor calcium permeability is essential for human cognition.”

Specifically, the investigators focused on CP-AMPA receptors in two distinct areas of the brain, the visual cortex, where neurons process visual information, and the hippocampus, where neurons respond to “where you are, where you are headed, or where you have been,” Hong says.

To conduct their research, the scientists developed novel adeno-associated virus vectors to replace calcium permeable AMPA receptors with impermeable counterparts and express them in the mouse brain. They say they hope these vectors can help treat disorders that arise from AMPA receptor mutations in the future.

To map out PV neuron selectivity, the scientists used advanced imaging techniques to observe neuron structure and activity deep within genetically engineered mice brains while showing them video stimuli.

“In most cases, we found that these PV neurons, which are typically less selective, became more selective to visual stimuli as well as spatial location when we swapped out CP-AMPA receptors for impermeable molecules, making inhibitory neurons act more like excitatory neurons,” Hong says.

The researchers say the high amount of CP-AMPA receptors in PV neurons is well-conserved across many species of mammals, including humans.

“Making neuron inhibition less selective makes our neural circuits more efficient than species that don’t have this molecular feature,” Hong says. “It probably also means that our neural networks are more stable.”

Hong says the new research may also have implications for machine learning used in artificial intelligence.

“In machine learning, there are many computerized ‘artificial’ neurons that are trained to be very selective or less selective,” he says. “We're trying to find how specific and less specific units can work together to give us smarter machines and smarter AI.”

Up next, the scientists intend to study other critical molecules known to change cognition. In clinical neuroscience, Hong says, a better understanding of which brain molecules contribute to biased neuronal computations in patients could advance the search for drug therapy targets in psychiatric disorders with a genetic component, a budding field Hong calls “neurocomputational therapeutics.”

In addition to Hong and Huganir, other scientists who contributed to this study are Juhyun Kim, Dong Won Kim, Richard C. Johnson, Nathachit Limjunyawong, Zhuonan Yang, David Cheon, Taeyoung Hwang, Amit Agarwal, Xinzhong Dong, Seth Blackshaw, Dwight E. Bergles and Solange P. Brown of Johns Hopkins; Thomas Hainmueller, Thibault Cholvin and Marlene Bartos of University of Freiburg; Joram Keijser and Henning Sprekeler of Technical University of Berlin; Soo Hyun Park and David A. Leopold of the National Institute of Mental Health; Fenna M. Krienen of Princeton University; and Steven A. McCarroll of Harvard Medical School.

Funding for this research was provided by National Institutes of Health grants R37NS036715 and U01DA056556.

DOI: 10.1038/s41586-024-08027-2


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.